Curaleaf (OTCMKTS:CURLF – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
Profitability
This table compares Curaleaf and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -2.62% | -0.88% | -0.26% |
| Orchestra BioMed | -184.60% | -149.61% | -54.15% |
Valuation and Earnings
This table compares Curaleaf and Orchestra BioMed”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 1.84 | -$231.07 million | ($0.13) | -76.85 |
| Orchestra BioMed | $33.48 million | 10.48 | -$52.70 million | ($0.85) | -6.87 |
Orchestra BioMed has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Curaleaf and Orchestra BioMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 0 | 2 | 3 | 3.60 |
| Orchestra BioMed | 1 | 0 | 6 | 0 | 2.71 |
Curaleaf presently has a consensus price target of $6.00, suggesting a potential downside of 39.94%. Orchestra BioMed has a consensus price target of $13.17, suggesting a potential upside of 125.46%. Given Orchestra BioMed’s higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Curaleaf.
Insider & Institutional Ownership
0.0% of Curaleaf shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Curaleaf has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Summary
Curaleaf beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
